TARS — Recent News Coverage
All news mentioning TARS in ESEN's AI-graded feed
News stories with TARS as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on TARS. See /coverage/TARS for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-08-06
NEUTRAL
NEUTRAL
CORR0.35
Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TARS) 2026-08-06
$TARS
◈ ESEN AI
Tarsus Pharmaceuticals released its 2026 Q2 earnings presentation on August 6, marking a routine disclosure of financial and operational results. The slide deck serves as the primary communication vehicle for investor u…
SEEKINGALPHA
·
2026-08-06
NEUTRAL
NEUTRAL
CORR0.15
Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals
$TARS
$ALKS
◈ ESEN AI
Tarsus Pharmaceuticals has announced an acquisition of Alkeus Pharmaceuticals, a consolidation move within the biopharmaceutical sector. This transaction represents typical M&A activity in the pharmaceutical space, wher…
MANILATIMES.NET
·
2026-08-06
NEUTRAL
BULLISH
CORR0.42
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
$TARS
◈ ESEN AI
Tarsus Pharmaceuticals (TARS) has secured $125 million in oversubscribed PIPE financing from qualified institutional buyers and accredited investors. The oversubscription indicates strong institutional demand for the co…
GLOBALNEWSWIRE
·
2026-08-06
NEUTRAL
BULLISH
CORR0.42
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
$TARS
◈ ESEN AI
Tarsus Pharmaceuticals is acquiring Alkeus Pharmaceuticals to consolidate eye care capabilities and gain access to gildeuretinol (ALK-001), a Phase 3 oral candidate targeting Stargardt disease. This transaction represen…
SEEKINGALPHA.COM
·
2026-07-24
NEUTRAL
NEUTRAL
CORR0.35
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching (TARS)
$TARS
◈ ESEN AI
Tarsus Pharmaceuticals (TARS) reported a sequential decline in net product sales during Q1 2026 versus Q4 2025, marking the first contraction since the commercial launch of Xdemvy. This reversal signals potential demand…
MANILATIMES.NET
·
2026-07-13
NEUTRAL
NEUTRAL
CORR0.15
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
$TARS
◈ ESEN AI
Tarsus Pharmaceuticals (TARS) disclosed an executive leadership transition with Chief Commercial Officer Aziz Mottiwala departing to lead a public medical device manufacturer. The departure removes a key commercial stra…
SEEKINGALPHA.COM
·
2026-07-09
HIGH
BULLISH
CORR0.72
Tarsus Pharmaceuticals, Inc. (TARS) iRenix Medical, Inc., - M&A Call - Slideshow (NASDAQ:TARS) 2026-07-09
$TARS
◈ ESEN AI
Tarsus Pharmaceuticals (TARS) has announced a material merger or acquisition involving iRenix Medical, signaling strategic portfolio expansion within the ophthalmology and specialty pharmaceutical space. M&A activity of…
GLOBALNEWSWIRE
·
2026-07-08
NEUTRAL
BULLISH
CORR0.42
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
$TARS
◈ ESEN AI
Tarsus Pharmaceuticals has acquired iRenix Medical and secured a late-stage ophthalmic asset (IRX-101) designed to address vision loss across a broad patient population. The acquisition represents a strategic vertical i…
EXPLORE OTHER FILTERS